SAN FRANCISCO — After spending a day with the Morgan, Lewis & Bockius San Francisco intellectual property team, French biomedical entrepreneur Rémi Dangla already had one take away.
“Here in the U.S., they see IP from a business perspective, not necessarily from a legal perspective,” Dangla said, explaining that U.S. entrepreneurs see purchasing patent licenses as a necessary business expense. “In France, you look at the IP field. If it’s blocked, you don’t go.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
